FDA: Link between fosamprenavir and MI, dyslipidemia
Links shared publicly online about this topic.
- 1,545total visits
FDA: Link between fosamprenavir and MI, dyslipidemia
Fosamprenavir calcium is associated with an increased risk of MI and dyslipidemia in HIV-infected adults, according to the FDA.
View full resource at theheart.org
Tags: HIV Medication, Mineral, Calcium, FDA, Lexiva
Most Recently Shared on December 8, 2009 at 6:11 pm By:
FDA warning: Increased MI, dyslipidemia with fosamprenavir http://bit.ly/5UVUcD #heartwire
Advertisement
